Transaction DateRecipientSharesTypePriceValue
21st October 2020Steve Gorlin5,000Open or private purchase$9.19$45,950.00
15th October 2020Steve Gorlin100Open or private purchase$10.27$1,027.00
15th October 2020Steve Gorlin5,000Open or private purchase$10.10$50,500.00
15th October 2020Steve Gorlin5,000Open or private purchase$10.01$50,050.00
15th October 2020Steve Gorlin4,000Open or private purchase$10.19$40,760.00
15th October 2020Steve Gorlin1,000Open or private purchase$10.18$10,180.00
9th October 2020Steve Gorlin282Open or private purchase$9.61$2,710.02
7th October 2020Steve Gorlin4,718Open or private purchase$9.42$44,443.56
22nd September 2020Steve Gorlin15,000Open or private purchase$10.00$150,000.00
19th August 2020John C Thomas20,000Open or private sale$9.19$183,800.00
Nant Kwest
Nant Kwest logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

NantKwest, Inc. engages in the development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.

Ticker: NK
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1326110
Employees: 148
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $103 M (0%)
Other Assets, Current: $67 Th (179%)
Assets, Current: $115 M (106%)
Property, Plant and Equipment, Net: $59 M (0%)
Other Assets, Noncurrent: $3 M (0%)
Assets: $196 M (37%)
Accounts Payable, Current: $4 M (127%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $17 M (47%)
Liabilities: $27 M (18%)
Common Stock, Value, Issued: $11 Th (10%)
Common Stock, Shares, Issued: $108 M (9%)
Additional Paid in Capital, Common Stock: $870 M (11%)
Retained Earnings (Accumulated Deficit): $701 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $100 Th (-4%)
Stockholders' Equity (Parent): $170 M (0%)
Liabilities and Equity: $196 M (37%)
Research and Development: $14 M (-49%)
Operating Income/Loss: $20 M (-47%)
Other Income, net: $139 Th (-59%)
Provision for income taxes: $4 Th (0%)